Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash

Seres Therapeutics Inc. (NASDAQ: MCRB) shares are down during Thursday's premarket session following the company's announcement of a strategic shift in its operations.

Benzinga • Feb 12, 2026

Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases

Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activities and will pause further investment, while efforts to seek funding for the study remain ongoing Company's runway extension actions, including reducing the workforce by approximately 30%, are expected to extend its cash runway through Q3 2026 Seres will focus on advancing development of its early-stage live biotherapeutic programs in Inflammatory and immune diseases and supporting the read-out of clinical results from the fully enrolled Investigator-sponsored SER-155 study in immune checkpoint related enterocolitis (irEC), a frequent and severe adverse events in recipients of ICI therapy, expected in early Q2 2026 CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that, following advancement of key startup activities for the SER-155 Phase 2 study in allo-HSCT, including the submission of a final protocol to the FDA, study site evaluation and qualification with its CRO, and manufacturing of Phase 2 study drug substance, Seres is pausing additional investment in that program and will shift its operational focus to high-value earlier-stage pipeline programs while continuing to seek funding for the SER-155 Phase 2 study.

GlobeNewsWire • Feb 12, 2026

Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy

Data demonstrate  clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients

GlobeNewsWire • Jan 6, 2026

3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround

Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.

Zacks Investment Research • Dec 29, 2025

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:30 a.m.

GlobeNewsWire • Nov 24, 2025

Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript

Seres Therapeutics, Inc. ( MCRB ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Carlo Tanzi Marella Thorell - Co-CEO, Co-President & CFO Matthew Henn - Executive VP & Chief Scientific Officer Dennis M. Walling - Senior VP of Clinical Development & Head of Clinical Research Teresa Young - Executive VP and Chief Commercial & Strategy Officer Conference Call Participants John Newman - Canaccord Genuity Corp., Research Division Joseph Thome - TD Cowen, Research Division Presentation Operator Good day, everyone, and thank you for standing by.

Seeking Alpha • Nov 5, 2025

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other resources to support SER-155 Phase 2 study; pending securing funding, interim clinical results anticipated within 12 months of study initiation Ongoing investigator-sponsored study in immune checkpoint related enterocolitis expected to inform broader SER-155 opportunity; initial study results anticipated in early 2026 Seres recently implemented actions to reduce operating costs; based on these actions and current operating plans, Seres expects to fund operations through Q2 2026 CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported third quarter 2025 financial results and provided business updates.

GlobeNewsWire • Nov 5, 2025

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m.

GlobeNewsWire • Oct 30, 2025

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant (AMR) infections Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant (AMR) infections

GlobeNewsWire • Oct 29, 2025

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that new post hoc data from its SER-155 Phase 1b trial will be featured in an oral presentation at IDWeek 2025, taking place October 19–22 in Atlanta, Georgia.

GlobeNewsWire • Oct 14, 2025